Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 4/20 | 0.48 |
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731712 | 1.00 | TBXAS1 (0.48) | TBXAS1ESR1HCAR2ESR2CA12 | |
| SCHEMBL5732483 | 0.85 | APEX1 (0.52) | TBXAS1ESR1HCAR2ESR2CA12 | |
| SCHEMBL5732481 | 0.85 | APEX1 (0.52) | TBXAS1ESR1HCAR2ESR2CA12 | |
| SCHEMBL5731347 | 0.85 | KDM4E (0.48) | TBXAS1HCAR2PKMKDM4EHDAC8 | |
| SCHEMBL5731345 | 0.85 | KDM4E (0.48) | TBXAS1HCAR2PKMKDM4EHDAC8 | |
| SCHEMBL5731707 | 0.83 | CA12 (0.57) | ESR1CA12AKR1B10CA1CA2 | |
| SCHEMBL8921111 | 0.79 | TBXAS1 (0.68) | TBXAS1ESR1HCAR2ESR2CA12 | |
| SCHEMBL2772402 | 0.74 | TBXAS1 (0.71) | TBXAS1ESR1HCAR2ESR2CA12 | |
| SCHEMBL459101 | 0.74 | TBXAS1 (0.71) | TBXAS1ESR1HCAR2ESR2CA12 | |
| SCHEMBL5732104 | 0.74 | FFAR1 (0.49) | TBXAS1CA1CA2FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1008346-B1 | NF-kB INHIBITORS CONTAINING BENZOQUINONE DERIVATIVES | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-02-15 | — | — | EP | disclosed |
| US-6943196-B1 | NF-κB inhibitor comprising phenylmethyl benzoquinone as the active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-09-13 | — | — | US | disclosed |
| CN-1212861-C | Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing NF-K B inhibitors as the active ingredient | DAIICHI SUNTORY PHARMACEATICAL (JP) | 2005-08-03 | — | — | CN | disclosed |
| CN-1181817-C | NF-KB inhibitors containing as active ingredient phenylmethyl benzoquinone | ��һ��������ҩ��ʽ���� | 2004-12-29 | — | — | CN | disclosed |
| US-6703421-B1 | ADMINISTERING NF-KAPPA B INHIBITOR | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| CN-1335777-A | Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing NF-K B inhibitors as the active ingredient | SUNTORY LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1132093-A1 | PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2001-09-12 | — | — | EP | disclosed |
| CN-1262618-A | NF-KB inhibitors containing as active ingredient phenylmethyl benzoquinone | SUNTORY LTD (JP) | 2000-08-09 | — | — | CN | disclosed |
| EP-1008346-A1 | NF-$g(k)B INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE | SUNTORY LIMITED (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | NFKBIA, NFKB2, NFKB1 | TBXAS1 1015/4885ESR1 1755/4885HCAR2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.